High-Risk Screening for Fabry Disease in a Canadian Cohort of Chronic Kidney Disease Patients.

•A high-risk screening study was performed for patients with chronic kidney disease.•Globotriaosylceramide (Gb3) was analyzed in dried urine spots by LC-MS/MS.•A total of 397 participants were recruited in four centers across Canada.•No Fabry patients were detected in this study.•Chronic kidney disease might be associated with increased urinary Gb3 concentrations.